In contrast, a LIMK inhibitor developed by BMS (BMS3 or LIMKi3), has no anti-tumor effect when administered in vivo to mice bearing xenografted breast cancer tumors (Li et al., 2013b). Here, LIMK1 is linked to neoplasm.